

# Changes / updates to clinical trial legislation and approvals




# Health Research Authority (HRA)



**Health Research  
Authority**

[Guidance on changes to the clinical trials  
regulations - Health Research Authority](#)

# Guidance on changes to the clinical trials regulations



Home > Planning and improving research >  
Policies, Standards & Legislation >  
Clinical Trials of Investigational Medicinal Products (CTIMPs) >  
Clinical trials regulations reform >

## Guidance on changes to the clinical trials regulations

### Within this section

- Definitions and terminology →
- Pharmacovigilance →
- The approvals process for clinical trials →
- Simplified arrangements for consent in clinical trials →
- Research Ethics Committees that review clinical trials →
- Research transparency requirements for clinical trials →

On 28 April 2025, the United Kingdom (UK) Parliament and Northern Ireland Assembly approved the [The Medicines for Human Use \(Clinical Trials\) \(Amendment\) Regulations 2025](#).

These new regulations introduce changes to the [Medicines for Human Use \(Clinical Trials\) Regulations 2004](#) which currently govern the regulation of clinical trials involving investigational medicinal products (CTIMPs) in the UK.

The changes to the regulations are based on feedback from a [public consultation](#) in 2023, which included input from various stakeholders on beneficial changes to the existing legislation.

While Parliament has approved the updates, the new regulations will not come into force until 28 April 2026. This means that CTIMPs will continue to follow the Medicines for Human Use (Clinical Trials) Regulations 2004 until 27 April 2026.

The [existing guidance on the HRA website](#) will give you up to date information on how you should submit, manage and conduct CTIMPs in compliance with the 2004 regulations.

When the new regulations do come into force, they will apply across all four nations of the UK (England, Wales, Scotland and Northern Ireland). All clinical trials taking place in the UK will be required to comply with the updated regulations.

To help you understand and prepare for the new requirements, we have developed guidance that outlines the changes:

## New definitions

- Non-investigational medicinal product
- Notifiable trial
- Public registry



# Pharmacovigilance

- Suspected unexpected serious adverse reactions (SUSARs) and annual safety reports
- Urgent safety measures (USMs)



# The approvals process for clinical trials



# Submission of applications

April 2026						
S	M	T	W	T	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

Tuesday, Apr 28th 2026



Medicines &  
Healthcare products  
Regulatory Agency




Health Research  
Authority




Ymchwil Iechyd  
a Gofal **Cymru**  
Health and Care  
Research **Wales**

# The approvals process for applications









# Initial application timeframes and process



# Initial application timeframes and process





# Initial application timeframes and process



## Initial review outcomes

- favourable opinion
- favourable opinion subject to conditions
- unable to issue an opinion

# Initial application timeframes and process



# The approvals process for modifications (formerly known as amendments)


what are other  
words for  
amendment?





correction, improvement,  
revision, emendation, change,  
reform, modification,  
alteration, amelioration



# Modification timeframe and process






# Modification timeframe and process





# Modification timeframe and process





## MHRA and REC reviewing a response to a request for further information



# MHRA and REC requesting modifications post-approval



## When can the REC or MHRA request a modification?




## Approval lapsing for trials with no recruitment



# Simplified arrangements for consent in clinical trials

- What 'simplified arrangements' may be used?



# Research Ethics Committees that review clinical trials

- Constitution of RECs
- Attendance requirements for full meetings of the REC





# Research transparency requirements for clinical trials



# New IRAS



**COMING  
SOON**

## References

- [Guidance on changes to the clinical trials regulations - Health Research Authority](#)

## Contact

- Email:

Gurmel.Bhachu@wales.nhs.uk

- LinkedIn:

Gurmel Bhachu

